We serve Chemical Name:1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol CAS:445441-74-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol
CAS.NO:445441-74-7
Synonyms:1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-ol
Molecular Formula:C15H20N2O
Molecular Weight:244.33200
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:422.1ºC at 760 mmHg
Density:1.18g/cm3
Index of Refraction:1.621
PSA:28.40000
Exact Mass:244.15800
LogP:2.63100
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-ol Use and application,1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-ol technical grade,usp/ep/jp grade.
Related News: At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol manufacturer At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol supplier Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. 1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol vendor At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.
